What is OncoVEX?
OncoVEX: A family of oncolytic herpes simplex viruses optimised for therapeutic use.
Is T-VEC a vaccine?
T-VEC is the first genetically modified herpes simplex virus-1-based oncolytic immunotherapy approved by FDA and EMA for the treatment of unresectable, cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery [72,73].
When was T-VEC approved by the FDA?
TVEC was first described in 2003 and approved by the FDA in October 2015 to treat advanced melanoma.
Who developed T-VEC?
Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer. Immunotherapy. 2016 Feb;8(2):103-6.
Is Imlygic a gene therapy?
Imlygic is a modified genetic therapy inserted directly into tumors with a viral vector, where the gene replicates and produces a protein that stimulates an immune response to kill cancer cells.
How long does it take for T-VEC to work?
On average, patients who take T-VEC could see a response in less than five months, sometimes much sooner. There are mild to moderate side effects that typically diminish within a few days. Treatment occurs every 2-3 weeks and is done during a short office visit, with no hospital admission.
What is T-VEC used for?
A drug used to treat melanoma that has recurred (come back) after surgery. It is used in patients whose cancer is in the skin and lymph nodes and cannot be removed by surgery. It is also being studied in the treatment of other types of cancer.
Is T-VEC FDA approved?
On October 27, the U.S. Food and Drug Administration (FDA) approved the first oncolytic virus therapy, talimogene laherparepvec (T-VEC, or Imlygic®). The agency approved T-VEC for the treatment of some patients with metastatic melanoma that cannot be surgically removed.
How is Imlygic administered?
Administer IMLYGIC by injection into cutaneous, subcutaneous, and/or nodal lesions that are visible, palpable, or detectable by ultrasound guidance.
Is Imlygic a biologic?
27, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration ( FDA ) has approved the Biologics License Application for IMLYGIC™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous.
What is Imlygic used for?
This medication is used to treat a certain type of skin cancer (melanoma). It contains a live virus (cold sore virus) that has been weakened. Talimogene laherparepvec infects the cancer cells and works by slowing or stopping their growth.